Helicobacter pylori eradication: Role of individual therapy constituents and therapy duration

Fundamental and Clinical Pharmacology

Volumn 23, Issue 1, 2009, Pages 43-52

  Qasim, Asghar ^a   O'Morain, Colm A ^b   O'Connor, Humphrey J ^a  

^a Naas General Hospital   (Ireland)

^b The University of Dublin   (Ireland)

Author keywords

Eradication; Helicobacter pylori; Pharmacokinetics; Proton pump inhibitors; Therapy duration

Indexed keywords

AMOXICILLIN; ANTICONVULSIVE AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; IMIDAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH PH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ALGORITHMS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS;

EID: 61349108766     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00635.x     Document Type: Review

References (99)

1. Malfertheiner P., Megraud F., O'Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2007) 56 772 781.
2. Howden C.W., Hunt R.H. ACG treatment guidelines: management of Helicobacter pylori infection. Am. J. Gastroenterol. (1998) 93 2330 2338.
3. Lam S.K., Talley N.J. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. (1998) 13 1 12.
4. van Kemseke C., Belaiche J. Guidelines for the management of Helicobacter pylori: recent opinion of the French National Society of Gastroenterology (trans). Rev. Med. Liege. (2000) 55 345 349.
5. Lee J.M., Deasy E., O'Morain C.A. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur. J. Gastroenterol. Hepatol. (2000) 12 433 437.
6. Ishioka H., Mizuno M., Take S. et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion (2007) 75 63 68.
7. Ford A.C., Delaney B.C., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006 2 : CD 003840.
8. Moayyedi P., Soo S., Deeks J. et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane. Database. Syst. Rev. 2006 2 : CD 002096.
9. Calabrese C., Di Febo G., Areni A. et al. Pantroprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14 1613 1617.
10. Wong B.C., Wang W.H., Wong W.M. et al. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomised controlled study. Aliment. Pharmacol. Ther. (2001) 15 843 850.
11. Hurenkamp G.J., Van Der Ende A., Grundmeijer H.G. et al. Equally high efficacy of 4,7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer diseases. Aliment. Pharmacol. Ther. (2000) 4 1065 1070.
12. O'Connor H.J., McLouchlin R., Kelly S. et al. Lansoprazole triple therapy for Helicobacter pylori - is 5 days enough? Aliment. Pharmacol. Ther. (1998) 12 273 276.
13. Neville P.M., Everett S., Langworthy H. et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment. Pharmacol. Ther. (1999) 13 497 501.
14. Isomoto H., Furusu H., Morikawa T. et al. 5-days vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2000) 14 1619 1623.
15. Catalano F., Catanzaro R., Branciforte G. et al. Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. J. Clin. Gastroenterol. (2000) 31 130 136.
16. Nagahara A., Miwa H., Yamada T. et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2001) 15 417 421.
17. Veldhuyzen van Zanten S.J.O., Bradette M., Farley A. et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther. (1999) 13 289 295.
18. Malfertheiner P., Bayerdorffer E., Diete U. et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. (1999) 13 703 712.
19. Damman H.G., Folsch U.R., Hahn E.G. et al. Eradication of H pylori with pantoprazole, clarithromycin, and metrinidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter (2000) 5 41 51.
20. Pilotto A., Leandro G., Franceschi M. et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment. Pharmacol. Ther. (1999) 13 667 673.
21. Pilotto A., Franceschi M., Leandro G. et al. Efficacy of 7-day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J. Gastroenterol. Hepatol. (1999) 14 468 475.
22. Miwa H., Yamada T., Sato K. et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig. Dis. Sci. (2000) 45 77 82.
23. Paoluzi P., Iacopini F., Crispino P. et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-centre randomised study. Helicobacter (2006) 11 562 568.
24. Treiber G. Treating H. pylori shorter than one week - a real future perspective? Z. Gastroenterol. (2000) 38 807 812.
25. Treiber G., Wittig J., Ammon S. et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch. Intern. Med. (2002) 162 153 160.
26. Malizia T., Tejada M., Marchetti F. et al. Synergistic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. J. Antimicrob. Chemother. (1998) 41 (Suppl.b) 29 35.
27. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. (2000) 38 243 270.
28. Sakurai K., Takahashi H., Yamaguchi Y. et al. Importance of drug selection and the use of sensitivity tests in the eradication therapy for Helicobacter pylori. Nippon Rinsho (1999) 57 72 75.
29. Murakami K., Satoh R., Okimoto T. et al. Selection of antibiotics and planning of eradication for H. pylori infection. Nippon Rinsho (2001) 59 308 313.
30. Owen R.J., Ferrus M., Gibson J. Amplified fragment length polymorphism genotyping of metronidazole-resistant Helicobacter pylori infecting dyspeptics in England. Clin. Microbiol. Infect. (2001) 7 244 253.
31. Romano M., Marmo R., Cuomo A. et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. (2003) 1 273 278.
32. Qasim A., Sebastian S., Buckley M., O'Connor H., O'Morain C. Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. (2004) 2 85. discussion 85.
33. Marzio L., Coraggio D., Capodicasa S. et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter (2006) 11 237 242.
34. Furuta T., Shirai N., Kodaira M. et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H pylori. Clin. Pharmacol. Ther. (2007) 81 521 528.
35. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 53 1374 1384.
36. Megraud F. H pylori update on therapeutic options for Helicobacter pylori-related diseases. Curr. Infect. Dis. Rep. (2005) 7 115 120.
37. Pilotto A., Franceschi M., Rassu M. et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig. Liver. Dis. (2000) 32 667 672.
38. Peitz U., Hackelsberger A., Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs (1999) 57 905 920.
39. Xiao S.D., Liu W.Z., Hu P.J. et al. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment. Pharmacol. Ther. (2001) 15 81 86.
40. Perri F., Festa V., Clemente R. et al. Rifabutin-based 'rescue therapy' for Helicobacter infection in patients after failure of standard regimens. Aliment. Pharmacol. Ther. (2000) 14 311 316.
41. Gisert J.P., Calvet X., Bujanda L. et al. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter (2003) 8 90 94.
42. Qasim A., Sebastian S., Thornton O. et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment. Pharmacol. Ther. (2005) 21 91 96.
43. Di Caro S., Assunta Zocco M., Cremonini F. et al. Levofloxacin based regimens for te eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. (2002) 14 1309 1312.
44. Sezgin O., Altintas E., Ucbilek E. et al. Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population. Helicobacter (2007) 12 518 522.
45. Cammarota G., Cianci R., Cannizzaro O. et al. Efficacy of two one-week rabeprazole/levofloxacin - based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2002) 14 1339 1343.
46. Watanabe Y., Aoyama N., Shirasaka D. et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig. Liver. Dis. (2003) 35 711 715.
47. Perri F., Festa V., Merla A. et al. Randomised study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment. Pharmacol. Ther. (2003) 18 815 820.
48. Gisbert J.P., Fernandez-Bermejo M., Molina-Infante J. et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2007) 26 495 500.
49. Gisbert J.P., Bermejo F., Castro-Fernandez M. et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am. J. Gastroenterol. (2008) 103 71 76.
50. Gisbert J.P., Castro-Fernandez M., Bermejo F. et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am. J. Gastroenterol. (2006) 101 243 247.
51. Zullo A., Hassan C., De Francesco V. et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver. Dis. (2003) 35 232 236.
52. Nista E.C., Candelli M., Cremonini F. et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomised trial. Aliment. Pharmacol. Ther. (2003) 18 627 631.
53. McLoughlin R., O'Morain C.A., O'Connor H.J. Eradication of Helicobacter pylori: recent advances in treatment. Fundam. Clin. Pharmacol. (2005) 19 421 427.
54. Hirai M., Azuma T., Ito S. et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J. Gastroenterol. (1995) 30 461 464.
55. de Bortoli N., Leonardi G., Ciancia E. et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol. (2007) 102 951 956.
56. Lind T., Megraud F., Unge P. et al. The MACH2 Study: role of omeprozole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 116 248 253.
57. Andersson T., Andren K., Cederberg C. et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmcol. (1990) 29 557 563.
58. Delhotal-Landes B., Petite J.P., Flouvet B. Clinical pharmacokinetics of lansoprazole. Clin. Pharmacokinet. (1995) 28 458 470.
59. Huber R., Hartmann M., Bliesath H. et al. Phamacokinetics of pantoprazole in man. Int. J. Clin. Pharmacol. Ther. (1996) 34 185 194.
60. Gerloff J., Mignot A., Barth H. et al. Phamacokinetics and absolute bioavailabililty of lansoprazole. Eur. J. Clin. Pharmacol. (1996) 50 293 297.
61. Williams M.P., Sercombe J., Hamilton M.I. et al. A placebo-controlled trial of the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. (1998) 12 1079 1089.
62. Benet L.Z., Zech K. Pharmacokinetics-a relevant factor for the choice of a drug? Aliment. Pharmacol. Ther. (1994) 8 (Suppl. 1) 25 32.
63. Hartmann M., Theiss U., Hubber R. et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantrprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. (1996) 10 359 366.
64. Ohning G.V., Barbuti R.C., Kovoacs T.O.G. et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14 701 708.
65. Verdu E.F., Armstrong D., Idstrom J.P. et al. Intragastric ph during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand. J. Gastroenterol. (1996) 31 1151 1156.
66. Labenz J., Beker J.A., Dekker C.P. et al. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxicillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment. Pharmacol. Ther. (1997) 11 515 522.
67. Pantoflickova D., Dorta G., Jornod P. et al. Identification of the characteristics influencing the degree of antisecretory activity of PPI's. Gastroenterology (2000) 118 5895A.
68. Berardi R.R., Welage L.S. Proton-pump inhibitors in acid-related diseases. Am. J. Health Syst. Pharm. (1998) 55 2289 2298.
69. Richardson P., Hawkey C.J., Stack W.A. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs (1998) 56 307 335.
70. Scholtz H.E., Meyer B.H., Luus H.G. Comparison of the effects of lansoprazole, omeprazole and pantorazole on 24-hour gastric pH in healthy males. SA. J.Contin. Med. Educ. (1995) 85 915. (Abstract).
71. Kromer W., Kruger U., Huber R. et al. Differences in ph-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology (1998) 56 57 70.
72. Warrington S., Baisley K., Boyce M. et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 2 h intragastric pH and serum gastrin in healthy subjects. Aliment. Pharmacol. Ther. (2002) 16 1301 1307.
73. Miner P.B., Tutuian R., Castell D.O. et al. Intragastric acidity after switching from5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healty adult volunteers. Clin. Ther. (2006) 28 725 733.
74. Miehlke S., Madisch A., Kirsch C. et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantroprazole 40 mg twice daily-a randomised, two-way crossover study. Aliment. Pharmacol. Ther. (2005) 15 963 967.
75. Wilder-Smith C.H., Rohss K., Bondarov P. et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomised study. Aliment. Pharmacol. Ther. (2004) 15 1099 1104.
76. Hartmann D., Eickhoff A., Damian U. et al. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur. J. Gastroenterol. Hepatol. (2007) 19 133 137.
77. Miwa H., Ohkura R., Murai T. et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment. Pharmacol. Ther. (1999) 13 741 746.
78. Vergara M., Vallve M., Gisbert J.P., Calvet X. Meta-analysis: comparactive efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2003) 18 647 654.
79. Veldhuyzen Van Zanten S., Lauritsen K., Delchier J.-C. et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment. Pharmacol. Ther. (2000) 14 1605 1611.
80. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. (1996) 31 9 28.
81. Simon W.A., Budingen C., Fahr S. et al. The H+, K+ -ATPase inhibitor pantoprazole (BY1023/SK & F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem. Pharmacol. (1991) 42 347 355.
82. Meyer U.A. Interaction of proton pump inhibitors with cytochrome P450: consequences for drug interaction. Yale. J. Biol. Med. (1996) 69 203 209.
83. Gugler R., Hartmann M., Rudi J. et al. Lack of interaction of pantoprazole and diazepam in man. Gastroenterology (1992) 102 A77.
84. Humpheries T.J., Spera A.C., Laurent A.L. et al. Rabeprazole sodium (E3810), 20 mg daily does not affect the pharmacokinetics of phenytoin sodium in normal volunteers. Am. J. Gastroenterol. (1996) 91 : 1914(A).
85. Gugler R., Jensen J.C. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vivo. Gastroenterology (1985) 89 1235 1241.
86. Humphries T.J. A review of the drug-drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. Digestion (1998) 59 (Suppl. 3) 776. [Abstract].
87. Sakai T., Aoyama N., Kita T. et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. (2001) 18 721 727.
88. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. (2006) 44 297 302.
89. Furuta T., Shirai N., Takashima M. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. (2001) 69 158 168.
90. Saitoh T., Fukushima Y., Otsuka H. et al. Effects of rabeprazole, lansoprazole, and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. (2002) 16 1811 1817.
91. Timmer W., Ripke H., Kleist P. et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods. Find. Exp. Clin. Phamacol. (1995) 17 489 495.
92. Dekkers C.P.M., Beker J.A., Thjodleifsson B. et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of gastric ulcer-a European multicentre study. Aliment. Pharmacol. Ther. (1995) 9 19 24.
93. Dekkers C.P.M., Beker J.A., Thjodleifsson B. et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment. Pharmacol. Ther. (1999) 13 179 186.
94. Dittilo M., Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J. Clin. Gastroenterol. (1998) 27 (Suppl. 1) S163 S169.
95. Park J.B., Imamura L., Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol. Pharm. Bull. (1996) 19 182 187.
96. Tsuchiya M., Imamura L., Park J.-B. et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol. Pharm. Bull. (1995) 18 1053 1056.
97. Midolo P.D., Turnidge J.D., Lambert J.R. Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J. Antimicrob. Chemother. (1997) 39 331 337.
98. Gatta L., Perna F., Figura N. et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J. Antimicrob. Chemother. (2003) 51 439 442.
99. Kawakami Y., Akahane T., Yamaguch M. et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. (2000) 44 458 461.